The purpose of this study is to identify risk factors for thromboembolic and /or infectious complications in 3,000 patients with solid tumor and receiving a Percutaneous Central Venous Catheter (PCVC). A better understanding of the risk factors for these complications in this population would then allow interventional studies to be proposed to assess the benefit of prophylactic procedures in a sub-group of patients at most risk.

Inclusion Criteria:

• Patient with a neoplastic solid tumour with an indication for insertion of a PCVC.

Exclusion Criteria:

• Haematological neoplasm pathology, PCVC removal scheduled within 2 weeks of insertion,
• Therapeutic doses of anticoagulants required at inclusion,
• PCVC inserted by the femoral vein

cohort of consecutive patients